EIGR Eiger BioPharmaceuticals Inc

Price (delayed)

$8.20

Market cap

$278.4M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.83

Enterprise value

$202.4M

Sector: Healthcare
Industry: Biotechnology

Highlights

The equity has soared by 192% YoY and by 33% from the previous quarter
The company's net income has surged by 70% YoY and by 68% QoQ

Key stats

What are the main financial stats of EIGR
Market
Shares outstanding
33.95M
Market cap
$278.4M
Enterprise value
$202.4M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.2
Price to sales (P/S)
76.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
55.51
Earnings
Revenue
$3.65M
EBIT
-$16.95M
EBITDA
-$16.26M
Free cash flow
-$60.63M
Per share
EPS
-$0.83
Free cash flow per share
-$1.79
Book value per share
$3.72
Revenue per share
$0.11
TBVPS
$5.18
Balance sheet
Total assets
$175.52M
Total liabilities
$49.33M
Debt
$32.41M
Equity
$126.19M
Working capital
$152.37M
Liquidity
Debt to equity
0.26
Current ratio
9.7
Quick ratio
9.2
Net debt/EBITDA
4.67
Margins
EBITDA margin
-446%
Gross margin
98.5%
Net margin
-564%
Operating margin
-1,734.5%
Efficiency
Return on assets
-14.6%
Return on equity
-22.1%
Return on invested capital
-18.4%
Return on capital employed
-10.7%
Return on sales
-464.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EIGR stock price

How has the Eiger BioPharmaceuticals stock price performed over time
Intraday
-0.24%
1 week
-3.42%
1 month
-1.2%
1 year
-32.34%
YTD
-33.28%
QTD
-7.34%

Financial performance

How have Eiger BioPharmaceuticals's revenue and profit performed over time
Revenue
$3.65M
Gross profit
$3.59M
Operating income
-$63.24M
Net income
-$20.56M
Gross margin
98.5%
Net margin
-564%
The company's net income has surged by 70% YoY and by 68% QoQ
Eiger BioPharmaceuticals's operating income has increased by 5% YoY

Growth

What is Eiger BioPharmaceuticals's growth rate over time

Valuation

What is Eiger BioPharmaceuticals stock price valuation
P/E
N/A
P/B
2.2
P/S
76.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
55.51
Eiger BioPharmaceuticals's EPS has surged by 70% YoY and by 64% QoQ
The equity has soared by 192% YoY and by 33% from the previous quarter
The stock's price to book (P/B) is 45% less than its 5-year quarterly average of 4.0 and 33% less than its last 4 quarters average of 3.3

Efficiency

How efficient is Eiger BioPharmaceuticals business performance
Eiger BioPharmaceuticals's ROE has soared by 79% YoY and by 75% from the previous quarter
EIGR's return on assets has surged by 76% year-on-year and by 73% since the previous quarter
The company's return on invested capital has surged by 73% YoY and by 72% QoQ

Dividends

What is EIGR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EIGR.

Financial health

How did Eiger BioPharmaceuticals financials performed over time
EIGR's total assets has soared by 98% YoY and by 22% QoQ
The quick ratio has surged by 59% year-on-year and by 19% since the previous quarter
The debt is 74% lower than the equity
The equity has soared by 192% YoY and by 33% from the previous quarter
The company's debt to equity has shrunk by 65% YoY and by 24% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.